Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: A randomized clinical trial

Scandinavian Journal of Gastroenterology

Volumn 50, Issue 10, 2015, Pages 1185-1190

  Cao, Zhijun ^a   Chen, Qi ^a   Zhang, Wei ^a   Liang, Xiao ^a   Liao, Jingxian ^a   Liu, Wenzhong ^a   Xiao, Shudong ^a   Lu, Hong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

bismuth; drug therapy; Helicobacter pylori; levofloxacin; quadruple therapy

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; LANSOPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; TETRACYCLINE; BISMUTH;

ADULT; AGAR DILUTION; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CLEARANCE; BACTERIUM CULTURE; CONTROLLED STUDY; DIARRHEA; DISEASE ERADICATION; DISEASE SEVERITY; DROWSINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENDOSCOPY; EPIGASTRIC PAIN; FATIGUE; FEMALE; FOLLOW UP; HELICOBACTER INFECTION; HUMAN; INSOMNIA; INTENTION TO TREAT ANALYSIS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; METALLIC TASTE; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN ALLERGY; STOMACH PAIN; TREMOR; UREA BREATH TEST; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; GASTRIC MUCOSA; GASTROSCOPY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; IMMUNOHISTOCHEMISTRY; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; NEEDLE BIOPSY; ORAL DRUG ADMINISTRATION; PROCEDURES; PROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AGED; AMOXICILLIN; BIOPSY, NEEDLE; BISMUTH; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GASTRIC MUCOSA; GASTROSCOPY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IMMUNOHISTOCHEMISTRY; LANSOPRAZOLE; LEVOFLOXACIN; MALE; METRONIDAZOLE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84937142548     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2015.1037345     Document Type: Article

References (21)

1. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter 2007;12:275-8.
2. Furuta T, Graham DY. Pharmacologic aspects of eradication therapy for Helicobacter pylori Infection. Gastroenterol Clin North Am 2010;39:465-80.
3. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacter pylori infection-theMaastricht IV/Florence Consensus Report. Gut 2012;61:646-64.
4. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006;23: 35-44.
5. Miehlke S, Krasz S, Schneider-Brachert W, Kuhlisch E, Berning M, Madisch A, et al. Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection. Helicobacter 2011;16:420-6.
6. Sun QJ, Liang X, Zheng Q, Gu WQ, Liu WZ, Xiao SD, et al. Resistance of Helicobacter pylori to antibiotics from 2000 to 2009 in Shanghai. World J Gastroenterol 2010;16: 5118-21.
7. Gao W, Cheng H, Hu F, Li J, Wang L, Yang G, et al. The evolution of Helicobacter pylori antibiotics resistance over 10 years in Beijing, China. Helicobacter 2010;15:460-6.
8. Nista EC, Candelli M, Cremonini F, Cazzato IA, Di Caro S, Gabrielli M, et al. Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther 2003;18: 627-33.
9. Liao J, Zheng Q, Liang X, Zhang W, Sun Q, Liu W, et al. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. Helicobacter 2013;18:373-7.
10. Yee YK, Cheung TK, Chu KM, Chan CK, Fung J, Chan P, et al. Clinical trial: levofloxacin-based quadruple therapy was inferior to traditional quadruple therapy in the treatment of resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2007;26:1063-7.
11. Chuah SK, Tai WC, Hsu PI, Wu DC, Wu KL, Kuo CM, et al. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment-a pilot study. Helicobacter 2012;17:374-81.
12. Lu H, Zhang W, Graham DY. Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China. Eur J Gastroenterol Hepatol 2013;25:1134-40.
13. Rimbara E, Fischbach LA, Graham DY. Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol 2011;8:79-88.
14. Bilardi C, Dulbecco P, Zentilin P, Reglioni S, Iiritano E, Parodi A, et al. A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial. Clin Gastroenterol Hepatol 2004;2:997-1002.
15. Gisbert JP, Fernández-Bermejo M, Molina-Infante J, Pérez-Gallardo B, Prieto-Bermejo AB, Mateos-Rodríguez JM, et al. First-line triple therapy with levofloxacin for Helicobacter pylori eradication. Aliment Pharmacol Ther 2007;26:495-500.
16. Phillips RH, Whitehead MW, Lacey S, Champion M, Thompson RP, Powell JJ. Solubility, bsorption, and anti-Helicobacter pylori activity of bismuth subnitrate and colloidal bismuth subcitrate: in vitro data do not predict in vivo efficacy. Helicobacter 2000;5:176-82.
17. Mégraud F. The challenge of Helicobacter pylori resistance to antibiotics: the comeback of bismuth-based quadruple therapy. Therap Adv Gastroenterol 2012;5:103-9.
18. Zheng Q, Dai J, Li X, Ziao S. Comparison of the efficacy of pantoprazole-based triple therapy versus quadruple therapy in the treatment of Helicobacter pylori infections: a singlecenter, randomized, open and parallel-controlled study. Chin J Gastroenterol 2009;14:8-11.
19. Liang X, Xu X, Zheng Q, Zhang W, Sun Q, Liu W, et al. Efficacy of Bismuth-Containing Quadruple Therapies for Clarithromycin-, Metronidazole-, and Fluoroquinolone-Resistant Helicobacter pylori Infections in a Prospective Study. Clin Gastroenterol Hepatol 2013;11:802-7.
20. Malfertheiner P, Bazzoli F, Delchier JC, Celiñski K, Giguère M, Rivière M, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011;377: 905-13.
21. Graham DY, Calvet X. Guide regarding choice of secondline therapy to obtain a high cumulative cure rate. Helicobacter 2012;17:243-5.